ISARIC4C (Coronavirus Clinical Characterisation Consortium)

We are a UK-wide consortium of doctors and scientists committed to answering urgent questions about COVID-19 quickly, openly, and for the benefit of all. Over the last 9 years we have been preparing for such a major outbreak worldwide International Severe Acute Respiratory Infection Consortium Clinical Characterisation Protocol; our team deployed immediately and has been collecting data and samples since the first cases were reported in the UK.

Recruitment

We have recruited:

  • 249,822 patients at Tier Zero case report forms(CO-CIN)
  • 2,508 patients at Tier 1/2 (host/viral multiomics)
  • 16,252 critically-ill patients can also be recruited to a sister study, the ISARIC GenOMICC study

Analysis Platform

The ISARIC4C study has created an open-access integrated analysis platform for linked clincal data from across the NHS for a range of studies, including ISARIC4C, GenOMICC, PHOSP, COG-UK and UK-CIC.

Consortium details

Funding

ISARIC4C is funded by two major awards from UK Reasearch and Inovation (UKRI) and The National Institute For Health Research (NIHR). We share data and samples to get answers as fast as possible. We will not end this outbreak sitting on a biobank; our intention is to use every drop of every sample, now, to have the biggest possible impact on the COVID-19 crisis. Any investigators with the ability to contribute can access our data and samples. The ISARIC4C study provides a foundation for other studies, such as clinical trials of new treatments, to help better understand the best way to use interventions.

ISARIC4C

Sharing samples and data

ISARIC4C was designed from the outset as a foundation for the UK outbreak response, supporting re...

Impacting Policy

ISARIC4C and CO-CIN (Tier 0) feed data dynamically to Public Health Scotland, Public Health Engla...

Risk prediction: the 4C Mortality Score

BMJ 9 Mar 2020 Using data from 57, 824 hospital admissions, we developed and validated an easy-t...

Characterisation of hospitalised cases of COVID-19

BMJ: 2020; 369 Within weeks of being funded, we produced the largest study anywhere in the world...

Genetic mechanisms of severe Covid-19

MedRxiv September 2020; Nature online December 2020 In collaboration with the ISARIC GenOMICC st...

Clinical characterisation of Covid-19 in children

BMJ 2020;370:m3249 We have comprehensively characterised the burden and patterns of disease in c...

Characterisation of in-hospital complications associated with COVID-19

The Lancet, 17 July 2021 As well as death, severe COVID-19 disease has effects on many different...

Circulating histones play a central role in COVID-19-associated coagulopathy and mortality

Haematologica Early View 8 April 2021 COVID-19 has highlighted the lethal consequences of immuno...

Long Covid in adults discharged from UK hospitals after Covid-19

MedRxiv pre-prints 25 March 2021 It is emerging that long-term symptoms are often present in peo...

Evaluation of effectiveness of remdesivir in treating severe COVID-19

MedRxiv pre-prints 21 June 2021 Adults with severe COVID-19 treated with remdesivir were compare...

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19

The Lancet: Rheumatology May 07, 2021 Early in the pandemic it was suggested that pre-existing u...

Role of blood cytokines IL-6 and GM-CSF in severe COVID-19

Science Immunology 10 Mar 2021 We have identified new biomarkers of inflammation that both revea...

T cells target many different parts of the virus

Nature Immunology (4th September 2020)) This study by Yanchung Peng, Alex Mentzer, Tao Dong an...

Setting Serology Standards

Setting the standard ISARIC 4C defined the international reference standard for SARS-CoV-2 serol...

Viral spike variants evading antibody-mediated immunity

Cell 4 Mar 2021 We showed that the N439K viral mutation has enhanced binding affinity to the ACE...

Using a double binding antigen assay to detect and measure SARS-CoV-2 antibodies

Lancet Pre-Prints 5 Jan 2021 Hybrid DABA displayed attributes necessary for accurate and sensiti...

Impact of ethnicity

SSRN July 2020 We have carefully studied the effect of ethnicity on outcomes in hospitalised pat...

SARS-CoV-2 surface and air contamination in a healthcare setting

Clinical Infectious Diseases 8 Jul 2020 We have explored the mechanisms of viral transmission. O...

Supporting vaccine development

The Lancet, 15 August 2020 At the start of the pandemic, ISARIC4C was able to provide convalesce...

ICECAP autopsy study

American Journal of Respiratory and Critical Care Medicine 2021 ISARIC 4C resources and consorti...

Adverse outcomes in COVID-19 patients with underlying respiratory conditions

Lancet Respiratory Medicine 4 March 2021 Characterisation of 75 463 hospitalised COVID-19 patien...

Co-Infections, Secondary Infections, and Antimicrobial Usage

Lancet Microbe 2 June 2021 We investigated the frequency and microbiological details of bacteria...

COVID-19 and Cancer

Esmo Open 1 May 2020 The ISARIC4C investigators collaborated with Prof Carlo Palmieri and team...

Detection of antibodies to determine population exposure

Eurosurveillance 22 Oct 2020 ISARIC4C provided support to this study looking at population expos...

Developing methods of sequencing the virus

Viruses 14 Oct 2020 Sequencing the viral genome as the outbreak progresses is important, particu...

Vulnerability of Down's syndrome (DS) patients to severe COVID-19

EClinical Medicine 22 Feb 2021) Providing data and support to the Trisomy 21 Society, a study wa...

ISARIC4C within the global ISARIC-network

An alternate weekly data share is made with global ISARIC CCP partners in 42 countries and a summ...

Modelling the association of tiered restrictions with COVID-19 deaths and hospital admissions

Lancet Infectious Diseases 23 Dec 2020 To look at the impact of tiered restrictions, the team fi...

Multi-model forecasts to inform the response to COVID-19 in the UK

MedRxiv pre-print 4 Dec 2020 Groups of multi-model forecasts can inform the policy response to t...

Testing the tests

MedRxiv May 2020 We proposed and established a Diagnostic Evaluation Platform at the University ...

Outcomes of COVID-19 hospitalisation among patients with HIV

Clinical Infectious Diseases 23 Oct 2020 Providing data and support to the British HIV Associati...

Outcomes of hospitalised COVID-19 patients with interstitial lung disease

American Journal of Respiratory and Critical Care 15 Dec 2020 We completed an international mult...

Pulmonary Microthrombosis and Vasculitis in Life-Threatening Respiratory Virus Diseases

Open Forum Infectious Diseases 28 Dec 2020 This study, with support and resources provided by IS...

Symptom clusters

MedRxiv August 16th 2020. Because of the large scale of the ISARIC-4C study, we were able to d...

Using imaging in COVID-19 -- UK National COVID-19 Chest Imaging Database

European Respiratory Journal 13 Aug 2020 The National COVID-19 Chest Imaging Database (NCCID) is...

Viral RNA found in blood is not infectious

Wellcome Open Research 29 Jul 2020 Laboratory diagnosis of SARS-CoV-2 infection uses PCR to dete...

Remdesivir Statistical Analysis Plan

The Remdesivir Statistical Analysis Plan was approved on 16 December 2020.